- Price
- $5.47
- Day
- +3.21%
- Mkt Cap
- $573.75M
- 52W Range
- $0.55 – $8.00
- Volume
- 1.18M
- Beta
- 0.46
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Volatility and Risk Relmada Therapeutics has a
Read full article
ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by 1,364.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 451,918 shares of the company's stock after acquiring an additional 421,052 shares during the period. ADAR1 Capital Management LLC owned approximately 0.43%
Read full article
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa.
Read full article
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 10,647,441 shares, a growth of 75.7% from the June 15th total of 6,060,018 shares. Currently, 11.9% of the company's shares are sold short. Based on an
Read full article
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.
Read full article